Immunomodulatory Market

Immunomodulatory Market Size (2023 to 2028)

The global immunomodulatory market is poised to register a CAGR of 6.9% from 2023 to 2028 and is expected to grow from USD 197.9 billion in 2023 to USD 360.22 billion by 2028.

Impact of COVID-19 on the global immunomodulatory market:

The COVID-19 pandemic crisis has positively impacted the global immunomodulatory market. Doctors widely use immune suppressants to treat chronic inflammatory illnesses. Doctors must properly instruct patients while taking medication, considering the COVID-19 pandemic. The rising rate of disease after the pandemic affects the Immunomodulatory market to grow at a rising pace. During the early stages of the COVID-19 pandemic, the immunotherapies employing plasma, immunoglobulin, antibodies, and Immunomodulatory agents helped to boost immunity, which were valuable alternatives in the vaccine shortage situations. In December 2020, the Himalaya Drug Company announced that the herbal immunomodulatory was effective as an adjuvant treatment for patients affected by the coronavirus. Likewise, the usage of immunomodulatory agents has increased during the COVID-19 pandemic and impacted the immunomodulatory market favorably.

MARKET DRIVERS:

The growing prevalence of autoimmune diseases majorly propels the growth of the immunomodulatory market. Multiple sclerosis has been marked as the major leading cause of death after cardiovascular disorders. The growing number of clinical trials for the development of immunotherapeutic agents such as ozanimod and laquinimod in the treatment of multiple sclerosis is expected to fuel the demand for immunomodulator products and drive market growth. The growing number of clinical trials concerned with the treatment of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis and increasing acceptance of immunotherapies due to lower risk of adverse effects further favors the immunomodulatory market growth.

The growing number of R&D activities to provide advanced patient care contributes to the global market growth. An innovative experiment led to a combination of therapy with new or existing drug molecules that led to a rise in the pipeline candidate for several disease treatments, including rheumatoid arthritis, multiple sclerosis, and others. The rapid adoption of monoclonal antibodies fuels the growth rate of the immunomodulatory market. On a global scale, the incidence of chronic diseases such as cancer, rheumatoid arthritis and multiple sclerosis is rising. By modifying the immune system, monoclonal antibodies offer a tailored strategy to treat various disorders. The need for Immunomodulatory treatments such as monoclonal antibodies is rising along with the prevalence of these diseases. The monoclonal antibody has seen significant investments from the pharmaceutical industry. To assess their safety and effectiveness for a variety of illness indications, multiple studies are now being conducted. The growing use of monoclonal antibodies within the immunomodulatory market is attributed to the availability of more therapy alternatives and the successful clinical results of these investigations.

Factors such as the ongoing clinical trials to produce immunotherapeutic medications, such as laquinimod, and ozanimod, the rising need to treat autoimmune disorders such as rheumatoid arthritis, advancement in diagnostic tools, development of novel therapies and the presence of high clinical need for treatment for immune disorder promote the global immunomodulatory market growth.

MARKET RESTRAINTS:

A higher risk of infection exists, including both new latent infections and main infections. Hepatitis B and C infectious agents, infections caused by fungi, tuberculosis (TB), and HIV are examples of such illnesses. Progressive multifocal leukoencephalopathy (PML) is also quite likely. Therefore, patients must be checked for these risks or past encounters with infections linked to these disorders before the start of Immunomodulatory treatment. Furthermore, excessive doses of these medications used to treat autoimmune illnesses frequently result in the killing of tumor cells but also cause significant harm to the body's normal cells. Many individuals experience a variety of adverse effects as a result, including gastrointestinal issues, hair loss, exhaustion, skin issues, and others. The growth of the worldwide market for immunomodulatory is expected to be adversely affected by these side effects of autoimmune medications during the forecast period. Furthermore, stringent regulatory requirements for research studies are anticipated to impede global market growth.

REPORT COVERAGE:

This research report on the immunomodulatory market has been segmented and sub-segmented based on the product, application and region.

Immunomodulatory Market- Based on Product

• Immunosuppressants
• Immunostimulants

Based on the product, the immunosuppressant segment is expected to hold the leading share of the global immunomodulatory market during the forecast period. The availability of diverse products in this market that have the potential to treat several autoimmune illnesses is one of the major factors propelling the growth of the immunosuppressant segment in the global market. These medications weaken the body's immune defense and are employed to lessen the body's unwanted immune response in the treatment of autoimmune diseases such as multiple sclerosis (MS), alopecia areata, rheumatoid arthritis and lupus. In the U.S., figures from the National Kidney Foundation show that 8,769 individuals passed away while waiting for kidney transplants in 2021.

The immunostimulants segment is predicted to account for a notable share of the global market during the forecast period owing to the growing incidence of several autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Immunomodulatory Market – By Application:

• Respiratory
• Oncology
• Multiple sclerosis
• Others

Based on application, the oncology segment is expected to account for the largest share of the worldwide market during the forecast period owing to the growing prevalence of cancer worldwide, high demand for effective immunomodulatory treatments, advancements in immunotherapy such as including immune checkpoint inhibitors and CAR-T cell therapies and rising awareness of the potential of immunomodulation in cancer treatment and improved patient outcomes.

The multiple sclerosis segment is anticipated to account for a substantial share of the worldwide market in the coming years. Immunomodulatory drugs are used to manage autoimmune conditions like multiple sclerosis by modulating the immune response. The growing incidence of multiple sclerosis, the development of disease-modifying therapies that target specific aspects of the immune system in multiple sclerosis and increasing research efforts to understand the underlying immunological mechanisms of multiple sclerosis and develop targeted therapies drive the growth of the multiple sclerosis segment in the worldwide market.

Immunomodulatory Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Based on region, the North American region is expected to continue its domination in the global market throughout the forecast period owing to the presence of advanced healthcare infrastructure, a strong pharmaceutical industry and a high prevalence of chronic diseases. The growing patient population of multiple sclerosis across North America contributes to the regional market growth. For instance, multiple sclerosis afflicted nearly 640,000 individuals across the U.S. alone in June 2022, according to information provided by Cleveland Clinic. The U.S. accounted for the leading share of the North American market in 2022 and is expected to hold the major share of the North American market during the forecast period. Factors such as the well-established healthcare system with access to cutting-edge immunomodulatory treatments, high healthcare expenditure and robust research and development activities and favorable reimbursement policies supporting the adoption of immunomodulatory therapies primarily drive the growth of the U.S. market.

The Asia-Pacific region was the second-largest regional market in 2022 and is expected to showcase the fastest CAGR during the forecast period. The growing number of immunomodulator-related clinical investigations and the increasing aging population propel the APAC market growth. Factors such as the growing number of improvements in the healthcare infrastructure, rising healthcare expenditure and increasing awareness of immunotherapy among people of the APAC region drive the growth of the APAC market. China is expected to lead the immunomodulatory market in the Asia-Pacific region, followed by Japan and India are predicted to hold the major share of the APAC market during the forecast period. The growing burden of chronic diseases, the increasing number of initiatives from the governments of APAC countries to improve healthcare access and affordability and growing clinical trials and research collaborations in immunomodulation propel the Chinese market growth.

Europe is expected to witness a substantial share of the worldwide market during the forecast period owing to the growing aging population, increasing prevalence of autoimmune diseases and rising demand for advanced therapies. Germany is the most promising regional market for immunomodulatory therapies in Europe and is expected to capture the leading share of the European market during the forecast period. High incidence of autoimmune diseases and cancer, strong emphasis on evidence-based medicine and regulatory compliance and collaborations between pharmaceutical companies and academic research institutions drive the growth of the German market. On the other hand, European countries such as the UK and France are anticipated to account for a considerable share of the European market during the forecast period.

KEY MARKET PLAYERS:

Pfizer Inc., Acrotech Biopharma, LLC, Astellas Pharma Inc., Horizon Therapeutics Plc, Petrovax, Hoffmann-La Roche Ltd., Amgen Inc., Abbott Laboratories, Johnson & Johnson, Novartis AG, and Bristol-Myers Squibb Company are some of the major players in the global immunomodulatory market.

RECENT DEVELOPMENTS IN THE MARKET:

• In January 2022, Sun Pharma launched a dry eye treatment product in Canada named CEQUA, a calcineurin inhibitor immunomodulator that uses Nano micellar (NCELL) technology to improve the bioavailability and physicochemical stability of cyclosporine to promote ocular tissue penetration.
• In February 2021, Merck announced the acquisition of Pandion Therapeutics, in which the acquisition adds the pipeline of candidates targeting a broad range of Autoimmune Diseases. Pandion has used its TALON technology to build a strong pipeline of candidates that aim to regulate the immune response and could be used to treat a variety of autoimmune conditions.